FDA Warns CBD Companies About Medicinal Claims

Just Released! Get realistic market forecasts, state-by-state insights and benchmarks with the new 2024 MJBiz Factbook member program, now with quarterly updates. Make informed decisions.

Although plenty of businesspeople in the cannabis community regard various properties of the plant as effective medicine for a number of ailments, the U.S. Food and Drug Administration doesn’t necessarily agree.

The agency recently sent six strictly worded warning letters to companies across the country that peddle CBD-based products, telling all that they need to quit making medicinal claims or face legal action.

“Your products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are ‘new drugs,'” the FDA wrote to CBD Life Holdings in Arizona. “New drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from the FDA…You should take prompt action to correct the violations cited in this letter.”

Similar letters were sent to Hemp Oil Care in California, Twin Falls Bio Tech in South Carolina, and three Washington State companies: Purecbd.net, Canna Pet, and Canna Companion.

The companies were all warned to take action to rectify problems the FDA identified within 15 working days of receiving the letters.